Commentary|Videos|April 3, 2025
Exploring Other Potential Roles for Mirvetuximab Soravtansine in Ovarian Cancer
Fact checked by: Chris Ryan
Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, discuss other potential roles for mirvetuximab soravtansine in ovarian cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
An IDMC recommended continuing a phase 2 minimal residual disease study of IMNN-001 without modification following a favorable safety review.
Toon Van Gorp, MD, PhD, discusses key data with TUB-040 in platinum-resistant ovarian cancer and next steps for development.
The top 5 OncLive TV videos of the week cover insights in NSCLC, large granular lymphocytic leukemia, ovarian cancer, and myelofibrosis.
Long-term data from the L-MOCA trial showed encouraging OS outcomes with olaparib maintenance in Asian patients with platinum-sensitive, relapsed ovarian cancer.
CHMP has recommended EU approval of senaparib for advanced ovarian cancer based on FLAMES data.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
2
The OncFive: Top Oncology Articles for the Week of 9/27/2026
3
AUA Releases Guideline Amendment for NMIBC
4
Daraxonrasib Approval Signals a New Era for RAS-Targeted Therapy in Pancreatic Cancer
5